Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations

A novel scoring system for TIGIT expression in classic Hodgkin lymphoma

(2021) Ombretta Annibali et al.   Scientific Reports

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma

(2020) Kristiina Karihtala et al.   Cancers

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

(2020) Fathima Zumla Cader et al.   NATURE MEDICINE

The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma

(2020) Joji Nagasaki et al.   Blood Advances

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

(2020) Sarah Reinke et al.   BLOOD

Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma

(2020) Layal El Halabi et al.   Clinical Lymphoma Myeloma & Leukemia

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer

(2019) Niclas C. Blessin et al.   DISEASE MARKERS

Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy

(2019) Joseph G. Taylor et al.   HAEMATOLOGICA

Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients

(2019) Kirill V. Lepik et al.   LEUKEMIA & LYMPHOMA

Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It

(2019) Donatella Aldinucci et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative

(2019) Sanjay S. Patel et al.   BLOOD

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages

(2019) Di Lu et al.   Journal of Immunology Research

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

(2019) Justin Kline et al.   BLOOD

Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma

(2019) Mixue Xie et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma

(2019) Tomohiro Aoki et al.   Cancer Discovery

Mass cytometry of Hodgkin lymphoma reveals a CD4+exhausted T-effector and T-regulatory cell rich microenvironment

(2018) Fathima Zumla Cader et al.   BLOOD

Macrophage plasticity, polarization, and function in health and disease

(2018) Abbas Shapouri-Moghaddam et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

(2018) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

(2018) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment

(2018) Stephanie Sasse et al.   HAEMATOLOGICA

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

(2018) Peter Hollander et al.   PLoS One

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma

(2018) Wenchao Li et al.   BMC CANCER

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

(2016) R. Chen et al.   BLOOD

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

(2016) Bruce D. Cheson et al.   BLOOD

Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma

(2016) Baoping Guo et al.   BMC Medicine

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance

(2016) Donatella Aldinucci et al.   CANCER LETTERS

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Hodgkin lymphoma: Pathology and biology

(2016) Stephan Mathas et al.   SEMINARS IN HEMATOLOGY

Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome

(2016) TuDung T. Nguyen et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Classical Hodgkin Lymphoma with Reduced  2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

(2016) M. G. M. Roemer et al.   Cancer Immunology Research

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study

(2016) Claudio Agostinelli et al.   Lancet Haematology

Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma

(2015) Semra Paydas et al.   ANNALS OF HEMATOLOGY

The role of T cells in the microenvironment of Hodgkin lymphoma

(2015) Frederik Wein et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma

(2015) Young Wha Koh et al.   TUMOR BIOLOGY

Macrophage Polarization Reflects T Cell Composition of Tumor Microenvironment in Pediatric Classical Hodgkin Lymphoma and Has Impact on Survival

(2015) Mário H. M. Barros et al.   PLoS One

CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma

(2014) Jonathan L. Klein et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells

(2013) P. Greaves et al.   BLOOD

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

(2013) Sally Arai et al.   LEUKEMIA & LYMPHOMA

Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages

(2013) Mário Henrique M. Barros et al.   PLoS One

Hodgkin lymphoma

(2012) Ralf Küppers et al.   JOURNAL OF CLINICAL INVESTIGATION

Macrophages predict treatment outcome in Hodgkin's lymphoma

(2011) C. Steidl et al.   HAEMATOLOGICA

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape

(2010) Donatella Aldinucci et al.   JOURNAL OF PATHOLOGY

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

(2009) Simone Muenst et al.   HUMAN PATHOLOGY

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

(2009) Andreas Engert et al.   JOURNAL OF CLINICAL ONCOLOGY